Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: FDA Consumer Health Information Last Updated: Sep 7, 2017 - 10:06:33 PM



FDA Expands Caution About SimplyThick

By FDA Consumer Health Information
Sep 18, 2012 - 11:31:31 AM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page
(HealthNewsDigest.com) - FDA wants parents, caregivers and health care professionals to be aware that infants of any age may face an increased risk of developing a life-threatening condition if fed a thickening product called SimplyThick.

The agency has identified 22 infants who developed necrotizing enterocolitis (NEC), a condition in which tissue in the intestines becomes inflamed and dies, after being fed SimplyThick. Seven of those infants have died. FDA had issued an advisory in May 2011 that warned of the risk to infants born prematurely. Now, FDA is extending that advice to include infants on any age.

SimplyThick is a brand of thickening agent—available to consumers and medical centers—to help manage swallowing difficulties.

###

For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: [email protected] or 877-634-9180
HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com


Top of Page

HealthNewsDigest.com

FDA Approval
Latest Headlines


+ FDA Warns of Potential Contamination in Multiple Brands of Drugs, Dietary Supplements
+ FDA Approves New Treatment to Reduce the Risk of Breast Cancer Returning
+ FDA Unveils Plan to Eliminate Orphan Designation Backlog
+ FDA Investigates Findings of Hepatitis A Linked to Frozen Tuna
+ FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
+ FDA Approves First Cancer Treatment for Any Solid Tumor With a Specific Genetic Feature
+ FDA Approves Drug to Treat ALS
+ FDA Approves Urea Cycle Disorder Treatment for Use in Children as Young as Two Months
+ Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-mutated Acute Yeloid Leukemia (AML)
+ FDA Approves New Combination Treatment for Acute Myeloid Leukemia



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions